vitamin A palmitate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4197 79-81-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vitamin A palmitate
  • retinol palmitate
  • retinyl palmitate
  • Molecular weight: 524.87
  • Formula: C36H60O2
  • CLOGP: 12
  • LIPINSKI: 2
  • HAC: 2
  • HDO: 0
  • TPSA: 26.30
  • ALOGS: -6.81
  • ROTB: 21
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 61
kinase-selectivity-class AXL,CDK4,EIF2AK3,EPHB4,GRK2,MAP2K6,PDK4,PLK1,STK33,TEK,TTK 11
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 18, 1949 FDA HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Presbyacusis 109.70 29.59 21 1232 3021 90624173
Pleural thickening 108.32 29.59 21 1232 3227 90623967
Blood magnesium increased 107.32 29.59 21 1232 3387 90623807
Pleural fibrosis 106.19 29.59 21 1232 3575 90623619
Deafness neurosensory 92.73 29.59 21 1232 6820 90620374
Epigastric discomfort 90.62 29.59 21 1232 7547 90619647
Cyst 74.30 29.59 21 1232 16540 90610654
Blood potassium increased 69.62 29.59 21 1232 20728 90606466
Osteopenia 67.48 29.59 21 1232 22981 90604213
Skin lesion 57.49 29.59 21 1232 37344 90589850
Dry eye 51.87 29.59 22 1231 57909 90569285
Hypervitaminosis A 45.81 29.59 5 1248 9 90627185
Blood creatinine increased 37.40 29.59 21 1232 101365 90525829
Renal impairment 36.63 29.59 21 1232 105400 90521794
Bone cyst 36.01 29.59 8 1245 2370 90624824
Osteoarthritis 31.27 29.59 24 1229 195706 90431488
Osteosclerosis 31.26 29.59 8 1245 4312 90622882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 114.46 86.01 38 2199 13418 42605680
Blood phosphorus increased 105.04 86.01 35 2202 12490 42606608
Myasthenia gravis 103.89 86.01 37 2200 16100 42602998
Abdominal distension 102.29 86.01 57 2180 71678 42547420
Appendicitis 102.22 86.01 39 2198 20574 42598524
Ventricular fibrillation 97.69 86.01 42 2195 30081 42589017
Hyperphosphataemia 95.91 86.01 33 2204 12971 42606127
Blood uric acid increased 90.14 86.01 33 2204 15514 42603584

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 132.20 37.06 38 3364 14217 110571680
Blood phosphorus increased 114.19 37.06 35 3367 16305 110569592
Myasthenia gravis 112.74 37.06 37 3365 21474 110564423
Appendicitis 110.15 37.06 39 3363 28425 110557472
Hypervitaminosis A 109.77 37.06 14 3388 52 110585845
Ventricular fibrillation 106.43 37.06 42 3360 41271 110544626
Hyperphosphataemia 105.66 37.06 33 3369 16348 110569549
Blood uric acid increased 96.80 37.06 33 3369 21496 110564401
Abdominal distension 90.45 37.06 60 3342 175043 110410854
Incorrect route of product administration 82.60 37.06 40 3362 64021 110521876
Iron deficiency 81.80 37.06 28 3374 18448 110567449
Neuralgia 80.29 37.06 36 3366 48442 110537455
Hypophosphataemia 79.41 37.06 32 3370 33150 110552747
Sleep disorder therapy 74.11 37.06 21 3381 7450 110578447
Presbyacusis 72.86 37.06 17 3385 2802 110583095
Ascites 71.31 37.06 41 3361 92767 110493130
Analgesic therapy 70.11 37.06 20 3382 7264 110578633
Pleural thickening 69.70 37.06 17 3385 3382 110582515
Cardiogenic shock 68.52 37.06 34 3368 57304 110528593
Blood magnesium increased 67.71 37.06 17 3385 3806 110582091
Bacterial infection 66.21 37.06 31 3371 46005 110539892
Sleep disorder 65.76 37.06 52 3350 198592 110387305
Pleural fibrosis 65.70 37.06 17 3385 4291 110581606
Diabetes mellitus 61.00 37.06 38 3364 99343 110486554
Chronic obstructive pulmonary disease 60.18 37.06 39 3363 109119 110476778
Thrombosis 57.89 37.06 38 3364 108624 110477273
Epigastric discomfort 53.29 37.06 17 3385 8998 110576899
Drug therapy 52.54 37.06 16 3386 7275 110578622
Deafness neurosensory 52.20 37.06 17 3385 9602 110576295
Intentional product misuse 46.55 37.06 36 3366 132868 110453029
Stress 44.64 37.06 32 3370 105316 110480581
Cyst 43.24 37.06 17 3385 16479 110569418
Dry mouth 41.21 37.06 40 3362 199908 110385989
Multiple organ dysfunction syndrome 40.32 37.06 35 3367 151675 110434222
Osteopenia 38.36 37.06 17 3385 22192 110563705
Drug hypersensitivity 37.40 37.06 57 3345 454033 110131864
Bacteroides infection 37.23 37.06 10 3392 2909 110582988

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000975 Antioxidants
MeSH PA D016588 Anticarcinogenic Agents
MeSH PA D020011 Protective Agents
MeSH PA D014815 Vitamins
MeSH PA D018977 Micronutrients
CHEBI has role CHEBI:22586 antioxidant
CHEBI has role CHEBI:77746 human metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vitamin deficiency indication 85670002
Prevention of dental caries indication 426482000
Dental fluorosis contraindication 30265004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML MULTIPLE VITAMINS INJECTION ADULT APOTEX A210672 April 9, 2026 RX SOLUTION INTRAVENOUS Dec. 1, 2026 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Retinol-binding protein 4 Secreted Kd 6.74 CHEMBL
Amyloid beta A4 protein Membrane other IC50 6.75 CHEMBL
Alpha-synuclein Transporter IC50 6.72 CHEMBL
Beta-lactoglobulin Secreted Kd 7.44 CHEMBL

External reference:

IDSource
4020767 VUID
N0000179230 NUI
D00164 KEGG_DRUG
4017648 VANDF
4017669 VANDF
4020767 VANDF
4021164 VANDF
C0073115 UMLSCUI
CHEBI:17616 CHEBI
RTL PDB_CHEM_ID
CHEMBL1675 ChEMBL_ID
C014794 MESH_SUPPLEMENTAL_RECORD_UI
1D1K0N0VVC UNII
5280531 PUBCHEM_CID
DB00162 DRUGBANK_ID
11246 RXNORM
232172 MMSL
5678 MMSL
5680 MMSL
975 MMSL
d00402 MMSL
001000 NDDF
001002 NDDF
422160004 SNOMEDCT_US
82156005 SNOMEDCT_US
82622003 SNOMEDCT_US
C0042839 UMLSCUI
445354 PUBCHEM_CID
2243 INN_ID
D014801 MESH_DESCRIPTOR_UI
CHEBI:45479 CHEBI
1D1K0N0VVC INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Quflora FE Pediatric Drops HUMAN PRESCRIPTION DRUG LABEL 14 15370-102 LIQUID 1500 [iU] ORAL UNAPPROVED DRUG OTHER 11 sections
Quflora FE Pediatric Drops HUMAN PRESCRIPTION DRUG LABEL 14 15370-102 LIQUID 1500 [iU] ORAL UNAPPROVED DRUG OTHER 11 sections
Adult Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9007 INJECTION, SOLUTION 3300 [iU] INTRAVENOUS NDA 20 sections
Adult Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9015 INJECTION, SOLUTION 3300 [iU] INTRAVENOUS NDA 20 sections
Pediatric Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9023 INJECTION, SOLUTION 2300 [iU] INTRAVENOUS NDA 19 sections
Pediatric Infuvite Multiple Vitamins HUMAN PRESCRIPTION DRUG LABEL 13 54643-9023 INJECTION, SOLUTION 2300 [iU] INTRAVENOUS NDA 19 sections
Multi-Vitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 58657-325 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
Multi-Vitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 58657-325 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
Multi-Vitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 58657-326 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
Multi-Vitamin with Fluoride HUMAN PRESCRIPTION DRUG LABEL 10 58657-326 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
Multi-Vitamin Drops with Fluoride and Iron HUMAN PRESCRIPTION DRUG LABEL 10 58657-327 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
Multi-Vitamin Drops with Fluoride and Iron HUMAN PRESCRIPTION DRUG LABEL 10 58657-327 LIQUID 1500 [iU] ORAL unapproved drug other 10 sections
AQUASOL A Parenteral Human Prescription Drug Label 1 64980-721 INJECTION, SOLUTION 15 mg INTRAMUSCULAR NDA 12 sections
Vitalipid N HUMAN PRESCRIPTION DRUG LABEL 4 65219-335 EMULSION 330 [iU] INTRAVENOUS Unapproved drug for use in drug shortage 2 sections
Vitalipid N HUMAN PRESCRIPTION DRUG LABEL 4 65219-337 EMULSION 230 [iU] INTRAVENOUS Unapproved drug for use in drug shortage 2 sections
Vitalipid N HUMAN PRESCRIPTION DRUG LABEL 4 65219-339 EMULSION 230 [iU] INTRAVENOUS Unapproved drug for use in drug shortage 2 sections
Derma Anti-Wrinkles HUMAN OTC DRUG LABEL 3 82160-436 CREAM 0.90 mg TOPICAL unapproved drug other 13 sections